News summary

Lingrui Pharmaceutical: Obtained the drug registration certificate of Montelukast Sodium Chewable Tablets Securities Times Company News, Lingrui Pharmaceutical (600285) announced on the evening of April 18 that the company recently received approval and issuance from the State Food and Drug AdministrationmetalslugarcadeDrug Registration Certificate of Montelukast Sodium Chewable Tablets. Indications for this product are: suitable formetalslugarcade...

Newsletter text

Lingrui Pharmaceutical: Obtained the drug registration certificate for Montelukast Sodium Chewable Tablets Securities Times e Company News, Lingrui Pharmaceutical (600285) announced on the evening of April 18 that the company recently received the approval and issuance of Montelukast Sodium Chewable Tablets "Drug Registration Certificate" approved by the State Food and Drug Administration. The indications for this product are: it is suitable for the prevention and long-term treatment of asthma in children aged 2 to 14 years old, including the prevention of asthma symptoms during the day and at night, the treatment of asthma patients sensitive to aspirin, and the prevention of exercise-induced bronchoconstriction.